Monday, July 11, 2022 9:52:50 AM
July 11 2022 - 07:30AM
GlobeNewswire Inc.
Share On Facebook
Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, announced today that it has reached an agreement with the U.S. Food and Drug Administration (“FDA”) under the special protocol assessment (“SPA”) process on the design, endpoints and statistical analysis of a Phase 3 clinical trial for oral sulopenem etzadroxil-probenecid (“oral sulopenem”) for the treatment of uncomplicated urinary tract infections (“uUTI”). The SPA agreement provides that the design and planned analysis of the trial, as set out in the protocol submitted to the FDA, adequately addresses the objectives necessary to support the potential resubmission of the Company’s new drug application (“NDA") for oral sulopenem.
“We are pleased to have concluded discussions with the FDA and reached agreement on key elements of the trial design to support the potential resubmission of the NDA for oral sulopenem for uUTI under the SPA process,” said Corey Fishman, Chief Executive Officer. “The SPA underscores our alignment with the FDA on important regulatory, clinical and scientific requirements for our planned Phase 3 trial in uUTI and reflects our ongoing commitment to bring this valuable therapy to market. We are excited about this important milestone and are looking forward to starting recruitment for this trial as soon as possible.”
The pivotal study to be conducted pursuant to the SPA agreement is designed as a non-inferiority trial comparing oral sulopenem and Augmentin® (amoxicillin/clavulanate) and is entitled “A prospective, Phase 3, randomized, multi-center, double-blind study of the efficacy, tolerability, and safety of oral sulopenem etzadroxil/probenecid versus oral amoxicillin/clavulanate for treatment of uncomplicated urinary tract infections (uUTI) in adult women.” Patients will be randomized to receive either oral sulopenem twice daily for 5 days or Augmentin® twice daily for 5 days. The primary endpoint is the overall response (clinical and microbiologic combined response) at Day 12 of the study. The study is expected to enroll approximately 1,966 patients and is anticipated to start enrolling in the fourth quarter of 2022. Study start-up activities have already been commenced by the Company to enable timely initiation and recruitment.
Recent ITRM News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/15/2024 12:00:08 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/11/2024 08:01:41 PM
- Iterum Therapeutics to Present Data at IDWeek 2024 • GlobeNewswire Inc. • 10/10/2024 12:30:00 PM
- Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit • GlobeNewswire Inc. • 10/09/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/08/2024 01:15:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2024 09:20:07 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/30/2024 08:15:02 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/30/2024 11:30:02 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/24/2024 01:01:07 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/24/2024 12:59:25 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/23/2024 10:30:01 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/11/2024 08:50:02 PM
- Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women • GlobeNewswire Inc. • 09/10/2024 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/09/2024 10:15:02 AM
- Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference • GlobeNewswire Inc. • 09/06/2024 08:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/14/2024 08:15:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 11:30:26 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 11:15:36 AM
- Iterum Therapeutics Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/14/2024 11:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/14/2024 04:15:16 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 08/09/2024 09:28:56 PM
- Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 • GlobeNewswire Inc. • 08/07/2024 08:30:00 PM
- Iterum Therapeutics Announces Expiration and Results of Rights Offering • GlobeNewswire Inc. • 08/06/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 09:25:18 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/02/2024 08:30:02 PM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM